Cargando…

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer

INTRODUCTION: Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yinghui, Wang, Xu, Sun, Chao, Gao, Zhiru, He, Hua, Qiu, Shi, Guo, Ye, Ma, Xiaohui, Song, Junya, Ma, Kewei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939110/ https://www.ncbi.nlm.nih.gov/pubmed/36082491 http://dx.doi.org/10.1002/cam4.5217

Ejemplares similares

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
por: Xu, Yanjun, et al.
Publicado: (2019)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging
por: Liang, Qian, et al.
Publicado: (2019)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

A systematic review of re-detectable positive virus nucleic acid among COVID-19 patients in recovery phase
por: Gao, Zhiru, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
por: Yang, Bo, et al.
Publicado: (2022)

Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report
por: Sa, Huanlan, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
por: Fu, Shengya, et al.
Publicado: (2022)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

A systematic review of asymptomatic infections with COVID-19
por: Gao, Zhiru, et al.
Publicado: (2021)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report
por: Sun, Mengyao, et al.
Publicado: (2020)

Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study
por: Chen, Runzhi, et al.
Publicado: (2022)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
por: Gao, Zhiru, et al.
Publicado: (2022)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
por: Jiang, Tao, et al.
Publicado: (2021)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
por: Cao, Mengru, et al.
Publicado: (2023)

Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial
por: Lin, Jian-Xian, et al.
Publicado: (2021)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer
por: Baur, M, et al.
Publicado: (2005)

Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
por: Zhou, Na, et al.
Publicado: (2020)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
por: Hou, Zhenyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ebe6jf3va3f9oh6htbj0o3udm4